Free tool
FAERS Monitor: Unithroid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021210 or its brand name (Unithroid, Levothyroxine Sodium). Reports on generic versions are filed under their own applications.
Reports
102,450
Serious
70,776
69% of reports
Hospitalization
39,249
Death reported
8,406
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue8,376
- nausea7,357
- diarrhoea6,656
- headache6,480
- dyspnoea6,385
- drug ineffective5,502
- pain5,395
- dizziness5,136
- vomiting4,585
- asthenia4,398
- off label use4,180
- fall4,153
- malaise4,125
- arthralgia4,026
- pruritus3,519
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,059 |
| 2005 | 2,025 |
| 2006 | 2,195 |
| 2007 | 2,773 |
| 2008 | 4,028 |
| 2009 | 3,842 |
| 2010 | 4,322 |
| 2011 | 6,155 |
| 2012 | 6,837 |
| 2013 | 1,415 |
| 2014 | 1,740 |
| 2015 | 2,411 |
| 2016 | 3,188 |
| 2017 | 3,647 |
| 2018 | 4,174 |
| 2019 | 4,062 |
| 2020 | 5,493 |
| 2021 | 5,861 |
| 2022 | 7,465 |
| 2023 | 7,039 |
| 2024 | 7,410 |
| 2025 | 8,338 |
| 2026 | 5,970 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,951,709 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fallSignal | 4,153 | 2.6 | 2.5 | 4,036 |
| astheniaSignal | 4,398 | 2.4 | 2.3 | 3,678 |
| dyspnoeaSignal | 6,385 | 2.3 | 2.3 | 4,927 |
| fatigueSignal | 8,376 | 2.2 | 2.2 | 5,780 |
| headacheSignal | 6,480 | 2.1 | 2.1 | 3,980 |
| diarrhoeaSignal | 6,656 | 2.1 | 2.1 | 4,065 |
| dizzinessSignal | 5,136 | 2.1 | 2.1 | 3,102 |
| vomitingSignal | 4,585 | 2.0 | 2.0 | 2,363 |
| arthralgia | 4,026 | 2.0 | 1.9 | 2,025 |
| malaise | 4,125 | 1.9 | 1.9 | 1,899 |
| nausea | 7,357 | 1.9 | 1.9 | 3,321 |
| pruritus | 3,519 | 1.9 | 1.8 | 1,483 |
| pain | 5,395 | 1.8 | 1.8 | 1,997 |
| off label use | 4,180 | 1.0 | 1.0 | 2 |
| drug ineffective | 5,502 | 0.9 | 0.8 | 140 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.